Spruce Biosciences, Inc.
SPRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | -0.08 | -0.20 | -0.12 |
| FCF Yield | -331.19% | -30.25% | -82.83% | -17.70% |
| EV / EBITDA | 0.36 | -0.39 | -0.70 | -3.99 |
| Quality | ||||
| ROIC | -176.20% | -63.91% | -63.08% | -35.66% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.06 | 0.69 | 0.90 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -68.15% | 20.17% | -15.90% | -30.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.68 | 1.94 | 0.40 | 0.86 |
| Interest Coverage | -182.90 | -107.65 | -112.58 | -121.93 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |